Datapoint: Padcev Snags Expanded Approvals in Bladder Cancer

The FDA last week granted Seagen Inc. and Astellas Pharma’s Padcev two expanded bladder cancer indications, following a priority review. The antibody-drug conjugate now has regular approval as a third-line treatment for metastatic or locally advanced urothelial cancer, plus a new nod as a second-line therapy for bladder cancer patients who are ineligible for certain types of chemotherapy. For the treatment of bladder cancer, Padcev currently holds covered or better status for 54% of all insured lives under the pharmacy benefit. Under the medical benefit, Padcev is covered or better for 82% of lives.

SOURCE: MMIT Analytics, as of 7/14/

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today